ÐÓ°ÉÔ­´´

PathoQuest, based in Paris, specializes in next-generation sequencing (NGS) to fully identify pathogens for healthcare providers. Its metagenomic tests offer a significant advantage over traditional methods like culture tests and PCR, which often result in delayed or inaccurate pathogen identification. By providing more precise diagnostics, PathoQuest aims to reduce ineffective treatments and associated healthcare costs. This focus appeals to health tech companies seeking efficient, cutting-edge solutions. With backing from prominent investors, PathoQuest is well-positioned to make a broad impact in biotech, improving pathogen detection and patient outcomes.